SA News • Mon, Nov. 17
From other sites
at MarketWatch.com (May 27, 2014)
at MarketWatch.com (Jun 2, 2010)
at MarketWatch.com (Jun 1, 2010)
There is research on this stock available only to PRO subscribers.
5 Reasons Why We Believe Novogen Is Poised For Success
- In preliminary tests, Novogen’s new drugs have shown to be able to kill the full hierarchy of cancer cells including cancer stem cells.
- The 5-year survival rate of cancer is low. The market has been anticipating a new drug that is able to improve those odds. Novogen is highly likely to achieve that.
- Novogen will apply for an IND submission for 2 drugs (possibly 3) in H2 2014. Hence, now is the best time to buy with the best risk/reward ratio.
- Novogen’s new drugs have a high probability to pass IND and do well in clinical trials.
There are no Transcripts on NVGN.
Mon, Nov. 17, 12:47 PM
Fri, Oct. 3, 1:53 PM
- The Gastroenterology and Urology Devices Panel of the Medical Devices Advisory Committee voted against recommending regulatory approval of SonaCare Medical's Sonablate 450 for the treatment of recurrent prostate cancer in patients previously treated with external beam radiation therapy. The device utilizes high intensity focused ultrasound (HIFU) to ablate tissue.
- The panel's rejection was due to the fact that Sonacare's clinical trial data were based on an interim analysis of the first 100 patients in a planned 200-patient clinical trial. The company obviously believed the data were compelling enough to proceed with its submission prior to the conclusion of the study but the reviewers felt otherwise.
- The panel voted 7-3 against (1 abstention) recommending that the treatment was safe if used as intended; 9-2 against recommending that the treatment was effective if used as intended and 10-0 against recommending that the benefits outweigh the risks.
- Briefing docs
- Prostate cancer therapy-related tickers:(TKAI -2.1%)(MDVN +1.2%)(NYMX +4.8%)(EXEL -0.3%)(PGNX +2.8%)(MRK +1.8%)(ADXS +2.7%)(EBS +1.8%)(EDAP +3%)(ISIS +2.1%)(NVGN)(DNDN +0.7%)(ISR +1.4%)(OGXI +0.4%)
Mon, Sep. 29, 9:16 AM
Tue, Jun. 17, 9:18 AM
Tue, May. 27, 9:26 AM
- Shares of pico cap Novogen (NVGN) are up 15% premarket on modest volume in response to its announcement that it has identified a number of super-benzopyran (SBP) compounds with anti-cancer activity against human prostate cancer cells in vitro.
- Retail investors need to exercise caution here because there is a colossal amount of time, money and effort ahead if the company intends to seek regulatory clearance for any of these product candidates. Novogen's market cap is only $24M and it is thinly traded (34K/day). Another red flag is the involvement of SA Contributor Biotech Breakthroughs. His promotion of Atossa Genetics (ATOS) ~1 year ago provides informative background info.
Fri, May. 2, 1:06 PM
- Australian biotech Novagen (NVGN +0.5%) inks a collaboration deal with fellow Aussie Genea Biocells to accelerate testing of their super-benzopyran (SBP) drugs for degenerative diseases of the nervous system and muscles.
- Early stage research by the firms point to the effectiveness of SBPs in normalizing stem cells associated with some types of neurodegeneration and muscular dystrophy.
- Novagen CEO Dr. Graham Kelly says that SBPs are known to be effective in killing cancer stem cells but they observed that the drugs also appeared to normalize the behavior and appearance of cancer stem cells in certain circumstances. This observation prompted them to conduct further testing.
- The molecules will be tested in laboratory models across a range of degenerative diseases.
- The companies will pool their respective resources but each will retain its own IP and commercial opportunities.
Tue, Mar. 18, 9:13 AM
Tue, Mar. 18, 8:24 AM
- Novogen's (NVGN) Trx-1 demonstrated a "potent anti-cancer effect" in mice that were implanted with human ovarian cancer stem cells.
- The study showed that Trx-1, which Novogen is developing with Yale, was effective on its own.
- "Until now, we have not been able to identify a drug from any company that is effective in this model," said Yale's Gil Mor. "So it is very exciting to observe an anti-tumoral effect with Trx-1."
- Novogen's shares are +15.7% premarket. (PR)
Nov. 26, 2013, 9:34 AM| Comment!
Nov. 25, 2013, 8:35 AM
- Novogen (NVGN) trades higher by 15% premarket.
- The company says Trilexium (a lead drug candidate from subsidiary CanTx), "is highly effective at destroying ovarian cancer spheroid architecture."
- Essentially, researchers isolated ovarian cancer stem cells, let them form self-renewing spheroids, then injected the spheroids into mice.
- Here's what the researchers had to say: "Trilexium is the first drug in our hands that has been shown to penetrate and destroy the spheroid architecture. This observation demonstrates that Trilexium can diffuse into the spheroid and gives us confidence that it should be able to kill ovarian cancer tumors in vivo." (6-K)
Nov. 14, 2013, 12:45 PM
Nov. 14, 2013, 8:18 AM
- Shares of Novogen (NVGN) rally 24% premarket.
- The move may be attributable to what the company calls an "important discovery" in the fight against genetic and degenerative disorders.
- NVGN says its scientists "came to suspect that the action of [the company's] drugs is not so much the fact that the stem cells are cancerous, but that they are behaving abnormally."
- Building on this, NVGN began a "pilot study looking into [the drugs'] effect on abnormal stem cells responsible for causing degenerative diseases."
- In short, the company says "early data completely supports" its hypothesis. (PR)
Nov. 4, 2013, 12:16 PM
- Novogen (NVGN +11.2%) posts double-digit gains on above-average volume with no readily apparent catalyst to explain the move.
- The shares skyrocketed in mid-October after SA contributor Small-Cap Momentum Advisors predicted a buyout.
- Also on the move in the biotech space is Zalicus (ZLCS -10.3%).
- The shares are off sharply after the company reported Q3 results.
- Notably, ZLCS says top-line data from two Z160 trials is still expected in Q4 and the company intends to start a Phase 2 trial of Z944 "in an appropriate pain indication with a modified release formulation ... next year." (PR)
Oct. 28, 2013, 9:12 AM
Oct. 25, 2013, 12:45 PM
Oct. 16, 2013, 9:31 AM
NVGN vs. ETF Alternatives
Other News & PR